GAITHERSBURG, Md., Feb. 03, 2021 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases,
Novavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science
SYNDICATED 1 months ago GAITHERSBURG, Md., Feb. 01, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D, President of Research & Development, will present on NVX-CoV2373, the company’s COVID-19 vaccine, at The New York Academy of Science (NYAS) event, ‘The Quest for a COVID-19 Vaccine.’ Webinar details are as follows: Presentation title:Efficacy Data Updates from Novavax’ Protein-based Vaccine CandidateDate:February 2, 2021Time:4:00 pm ETPresenter:Dr. Glenn Novavax announced interim data last week on its protein-based COVID-19 vaccine candidate that demonstrated efficacy of 89.3% in a pivotal Phase 3 clinical trial taking place in the United Kingdom (UK). The data from this UK Phase 3 trial and a South Africa Phase 2b study were the first to demonstrate cl